Assignee: Sumitomo Pharmaceuticals Company, Limited

Location: Osaka, JP
No. of patents: 165

Number	Title	Issue Date
7192608	Method of manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules The present invention provides coated granules using drug granules containing a water soluble drug as an active ingredient at a high density, which is superior in uniform content and stability, and which is capable of providing a pharmaceutical preparation superior ...	03/20/2007
7067528	1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative Hydrates of N-[1-butyl-4-[3-[3-(hydroxy)propoxy]-phenyl]-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl]-N′-(2,6-diisopropyl-4-aminophenyl)urea hydrochloride of the formula: are quite excellent in stability than amorphous o...	06/27/2006
7052875	Stable gene preparations The invention is directed to the retention of the stability of formulations useful for a gene therapy during the preparation and preservation. In the invention, at least one saccharide and/or at least one non-hydrophobic amino acid and/or at least one organic acid h...	05/30/2006
7041297	Tumor antigen peptides originating in cyclophilin B Tumor antigen peptides derived from cyclophilins or derivatives thereof having the functionally equivalent properties; medicaments, prophylactics, or diagnostics for tumors comprising as an active ingredient such tumor antigen peptides or derivatives thereof, cyclop...	05/09/2006
6951866	Bicyclic pyrimidine compounds and therapeutic use thereof 1. A pyrimidine derivative of the formula (1) or a salt thereof; has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, aut...	10/04/2005
6939887	Benzimidazolidinone derivatives The present invention can provide novel compounds useful as orally administrable growth hormone releaser, more specifically a benzimidazolidinone derivative of formula (1) or a pharmaceutically acceptable salt thereof: (1) wherein ...	09/06/2005
6919361	Five-membered-ring compound A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substitute...	07/19/2005
6902730	Semaphorin gene: Semaphorin W The present invention provides Semaphorin W inhibiting neurite outgrowth, and a gene therefor, as well as other Semaphorins hybridizing to said Semaphorin W gene, modified proteins or partial peptides of said Semaphorin W, antibodies against said Semaphorin W, antis...	06/07/2005
6869609	Method for treatment of renal failure and occlusive lesion of blood vessels by administration of hepatocyte growth factor The invention presents a preparation for continuous intravenous administration containing hepatocyte growth factor (HGF) as an active ingredient. The preparation for continuous administration of the invention is effective at a lower dose as compared with single or f...	03/22/2005
6787560	Serotonin reuptake inhibitor A serotonin reuptake inhibitor containing a cyclic amine represented by the following formula, a prodrug thereof, or a pharmaceutically acceptable salt of said cyclic amine or prodrug as an active ingredient: wherein R	09/07/2004
6759429	Pyrrole derivatives Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, an optionally substituted C1-C4	07/06/2004
6756358	Therapeutic agent for cartilaginous diseases The present invention relates to a therapeutic agent for cartilaginous diseases, an accelerator for chondrocyte proliferation and an accelerator for proteoglycan production comprising HGF (hepatocyte growth factor) as an active component, and a treatment method for ...	06/29/2004
6756048	Long time drug-sustained release preparation The present invention relates to a sustained release preparation of a lipophilic drug, comprising a drug dispersion wherein the lipophilic drug and a water-soluble substance are dispersed, in a solid state at the body temperature of an animal or a human being to whi...	06/29/2004
6740515	Recombinant adenovirus Recombinant adenoviruses comprising the following sequences in the genome: (1) a left inverted terminal repeat: (2) a packaging signal: (3) a recombinase recognition sequence located at a region in between said left inverted terminal repeat and said packaging signal...	05/25/2004
6734205	Substituted guanidine derivatives A compound represented by the following formula: wherein R is a substituted or unsubstituted benzene ring, a fused polycyclic hydrocarbon ring which is substituted or unsubstituted, a monocyclic heterocyclic ring which i...	05/11/2004
6713477	Hydroxamic acid derivatives A hydroxamic acid derivative represented by formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which has a matrix metalo-proteinase inhibitor. ...	03/30/2004
6703225	Interferon-଱ A novel human IFN-଱ subtype and its derivative having an unprecedentedly high specific activity, DNA encoding these proteins, an expression vector having said DNA, a transformant transformed with said expression vector, a method of producing the abo...	03/09/2004
6692926	Recombinant human SM-11044-binding receptor proteins exhibiting ligand-binding activities, and their use Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the...	02/17/2004
6689745	Agent for ameliorating pancreatic function disorder Agents for protecting or ameliorating pancreatic cells and tissues which contains as the active ingredient a neurotrophic factor such as BDNF. By using these drugs, degenerative dropout of pancreatic cells and pancreatic hypofunction caused by diabetes, a...	02/10/2004
6673772	Dipeptide compounds and their use as antiviral agents A novel dipeptide compound inhibiting the enzymatic activity of HIV protease and an anti-AIDS medicine comprising this dipeptide compound as an effective component represented by formula (I) ##STR1## wherein R1, R2, and R3...	01/06/2004
6660478	CYP2A6 gene judgment methods There are provided a method of determining a genotype of CYP2A6 gene on the basis of a difference in gene structures of a wild-type gene of CYP2A6 and at least one kind of mutant-type gene associated with mutation of CYP2A6 gene; the method mentioned abov...	12/09/2003
6645971	Quinazolinone derivatives A compound given by general formula (1): ##STR1## [wherein T represents oxygen or sulfur atom, Y represents alkyl, cycloalkyl group, etc., ring W represents benzene ring, etc., R1 and R2 represent independently hydrogen atom, lower a...	11/11/2003
6613799	Liposoluble platinum (II) complex and preparation thereof New derivatives of platinum (II) complex are herein provided, which are liposoluble and applicable as antimicrobial agents and anticancer agents specific to the affected parts of patients and selectively transferred to the parts if they are used in combin...	09/02/2003
6599895	ଲ-lactam compounds and process for producing the same Novel ଲ-lactam compound of the formula [1]: ##STR1## wherein R1 is lower alkyl or hydroxy-substituted lower alkyl, R2 is H or lower alkyl, X is O or, S, R3 is H, metal or protecting group, W is a 6- or 7-membered nit...	07/29/2003
6576441	Semaphorin Z and gene encoding the same Novel semaphorin Z; a gene thereof; a partial peptide of the semaphorin Z; an antibody; a DNA or an RNA complementary to the semaphorin Z gene; a method for screening a semaphorin Z inhibitor by using the semaphorin Z; the semaphorin Z inhibitor obtained ...	06/10/2003
6576656	Oxindole derivative An oxindole of Formula 1 or a prodrug thereof, or a pharmaceutically acceptable salt thereof is useful for growth hormone releaser: ##STR1## wherein R1, R2, R3 and R4 are independently hydrogen, optionally subst...	06/10/2003
6566094	Semaphorin gene: Semaphorin Y Semaphorin Y inhibiting neurite outgrowth, and a nucleotide sequence therefor, as well as other Semaphorin sequences hybridizing to the Semaphorin Y sequence, modified proteins or partial peptides of Semaphorin Y, antibodies against Semaphorin Y, antisens...	05/20/2003
6562599	Single-stranded antibody against hepatitis B virus core protein, gene thereof, and therapeutic agent for hepatitis B containing these A DNA characterized by coding for a single-stranded antibody capable of binding to a hepatitis B virus core protein: a single-stranded antibody coding for the DNA: a therapeutic agent for hepatitis B comprising the single-stranded antibody as the active i...	05/13/2003
6517870	Oral formulation comprising biguanide and an organic acid An oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness....	02/11/2003
6472366	Hepatocyte growth factor for treatment of diabetes The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-de...	10/29/2002
6465254	Mutant loxP site and applications thereof Highly efficient gene integration or gene replacement in the higher eucaryote including animal cells can be performed by using mutant loxP site having the following properties (a)-(c) in the present invention. (a) a nucleotide sequence wherein, in a wild-type ...	10/15/2002
6458798	Bicyclic pyrimidine compounds and therapeutic use thereof A pyrimidine derivative of the formula (1) or a salt thereof; ##STR1## has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as system...	10/01/2002
6452008	Pyridone derivatives and process for preparing the same A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is pref...	09/17/2002
6436669	Semaphorin genes (I) The present invention provides a novel Semaphorin having neurite-outgrowth inhibition activity or proteins analogous thereto, peptide fragments of, or antibodies against, such proteins, genes encoding such proteins, expression vectors for said genes, tran...	08/20/2002
6433019	Neurotrophic factor secretion promoters The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secre...	08/13/2002
6420381	Naphthyridine derivatives A compound of the formula (I): ##STR1## wherein Ring A is substituted or unsubstituted pyridine ring, Y is substituted or unsubstituted alkyl, etc., R1 is hydrogen, or substituted or unsubstituted alkyl, etc., R2 is hydrogen or lower...	07/16/2002
6399658	Composition containing ascorbic acid L-ascorbic acid, L-ascorbic acid derivatives and salts thereof can reduce lactic acid levels in blood, and are useful for treating lactic acidosis and the like caused by administration of amoxapine, theophylline, metformin, phenformin, buformin, nalidixic...	06/04/2002
6391312	Remedies for diabetes The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-de...	05/21/2002
6384033	Amide derivative A compound of the formula: ##STR1## wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.; R	05/07/2002
6376469	Crystalline amrubicin hydrochloride ଲ-Type crystalline amrubicin hydrochloride having a powder X-ray diffraction pattern having average values of diffraction angle(2θ) and relative intensity as given in the following table: diffraction angle(2θ) relative inten...	04/23/2002

«First «Previous1 2 3 4 5 Next»Last»

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: Sumitomo Pharmaceuticals Company, Limited